复宏汉霖“贝伐珠单抗”眼科III期研究成功

医药地理
04 Apr

4月2日,复宏汉霖宣布HLX04-O治疗湿性年龄相关性黄斑变性(wAMD)中国患者的III期HLX04-O-wAMD-CN研究已成功达到预设的主要研究终点。基于该研究结果,复宏汉霖计划携手亿胜生物在中国递交HLX04-O的新药上市申请(NDA)。HLX04-O有望成为中国首个获批用于眼科相关疾病治疗的贝伐珠单抗制剂。该研究为一项多中心、随机、双盲、阳性对照的非劣效III期临床试验(n=388),...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10